The Transcription Factor Cux1 in Cerebellar Granule Cell Development and Medulloblastoma Pathogenesis

Cerebellum

Volumn 13, Issue 6, 2014, Pages 698-712

  Topka, Sabine ^a   Glassmann, Alexander ^a,c   Weisheit, Gunnar ^a   Schüller, Ulrich ^b   Schilling, Karl ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c Life Science Inkubator   (Germany)

Author keywords

Cerebellum; Cutl1; Cux1; DNA damage response; Medulloblastoma; p53

Indexed keywords

CUT LIKE HOMEOBOX 1 PROTEIN; PROTEIN P53; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; CUTL1 PROTEIN, MOUSE; CUX1 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; NUCLEAR PROTEIN; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE REGULATION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CEREBELLUM CORTEX; CONTROLLED STUDY; DNA DAMAGE; GRANULE CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; MEDULLOBLASTOMA; MEDULLOBLASTOMA CELL LINE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL MOTION; CEREBELLUM; DISEASE MODEL; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CEREBELLUM; DISEASE MODELS, ANIMAL; HOMEODOMAIN PROTEINS; HUMANS; MEDULLOBLASTOMA; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURAL STEM CELLS; NEUROGENESIS; NEURONS; NUCLEAR PROTEINS; REPRESSOR PROTEINS;

EID: 84911806684     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1007/s12311-014-0588-x     Document Type: Article

References (89)

1. Schüller U, Kho AT, Zhao Q, Ma Q, Rowitch DH. Cerebellar “transcriptome” reveals cell-type and stage-specific expression during postnatal development and tumorigenesis. Mol Cell Neurosci. 2006;33:247–59.
2. Ayrault O, Zhao H, Zindy F, Qu C, Sherr CJ, Roussel MF. Atoh1 inhibits neuronal differentiation and collaborates with Gli1 to generate medulloblastoma-initiating cells. Cancer Res. 2010;70:5618–27.
3. Di C, Liao S, Adamson DC, Parrett TJ, Broderick DK, Shi Q, et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res. 2005;65:919–24.
4. Alcalay NI, Vanden Heuvel GB. Regulation of cell proliferation and differentiation in the kidney. Front Biosci. 2009;14:4978–91.
5. Xu H, He J-H, Xiao Z-D, Zhang Q-Q, Chen Y-Q, Zhou H, et al. Liver-enriched transcription factors regulate microRNA-122 that targets CUTL1 during liver development. Hepatology. 2010;52:1431–42.
6. Kedinger V, Nepveu A. The roles of CUX1 homeodomain proteins in the establishment of a transcriptional program required for cell migration and invasion. Cell Adhes Migr. Landes Bioscience; 2010;4:348–52.
7. Michl P, Ramjaun AR, Pardo OE, Warne PH, Wagner M, Poulsom R, et al. CUTL1 is a target of TGF(beta) signaling that enhances cancer cell motility and invasiveness. Cancer Cell. 2005;7:521–32.
8. Ripka S, Neesse A, Riedel J, Bug E, Aigner A, Poulsom R, et al. CUX1: target of Akt signalling and mediator of resistance to apoptosis in pancreatic cancer. Gut. 2010;59:1101–10.
9. Kühnemuth B, Michl P. CUX1 (cut-like homeobox 1). Jean-Loup Huret (Editor-in-Chief); INIST-CNRS (Publisher); 2012.
10. Harada R, Vadnais C, Sansregret L, Leduy L, Bérubé G, Robert F, et al. Genome-wide location analysis and expression studies reveal a role for p110 CUX1 in the activation of DNA replication genes. Nucleic Acids Res. Oxford University Press; 2008;36:189–202.
11. Mcnerney ME, Brown CD, Wang X, Bartom ET, Karmakar S, Bandlamudi C, et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. 2013;121.
12. Wong CC, Martincorena I, Rust AG, Rashid M, Alifrangis C, Alexandrov LB, et al. Inactivating CUX1 mutations promote tumorigenesis. Nat Genet. Nature Publishing Group; 2013.
13. Nieto M, Monuki ES, Tang H, Imitola J, Haubst N, Khoury SJ, et al. Expression of Cux-1 and Cux-2 in the subventricular zone and upper layers II–IV of the cerebral cortex. J Comp Neurol. 2004;479:168–80.
14. Cubelos B, Sebastián-Serrano A, Kim S, Redondo JM, Walsh C, Nieto M. Cux-1 and Cux-2 control the development of Reelin expressing cortical interneurons. Dev Neurobiol. 2008;68:917–25.
15. Cubelos B, Sebastián-Serrano A, Beccari L, Calcagnotto ME, Cisneros E, Kim S, et al. Cux1 and Cux2 regulate dendritic branching, spine morphology, and synapses of the upper layer neurons of the cortex. Neuron. 2010;66:523–35.
16. Reardon DA, Michalkiewicz E, Boyett JM, Sublett JE, Entrekin RE, Ragsdale ST, et al. Extensive genomic abnormalities in childhood medulloblastoma by comparative genomic hybridization. Cancer Res. 1997;57:4042–7.
17. Nishizaki T, Harada K, Kubota H, Ozaki S, Ito H, Sasaki K. Genetic alterations in pediatric medulloblastomas detected by comparative genomic hybridization. Pediatr Neurosurg. 1999;31:27–32.
18. Avet-Loiseau H, Vénuat AM, Terrier-Lacombe MJ, Lellouch-Tubiana A, Zerah M, Vassal G. Comparative genomic hybridization detects many recurrent imbalances in central nervous system primitive neuroectodermal tumours in children. Br J Cancer. 1999;79:1843–7.
19. Tong CYK, Hui ABY, Yin X-L, Pang JCS, Zhu X-L, Poon W-S, et al. Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization. J Neurosurg. 2004;100:187–93.
20. Schüller U, Heine VM, Mao J, Kho AT, Dillon AK, Han Y-G, et al. Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell. 2008;14:123–34.
21. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101–8.
22. Borovkov AY, Rivkin MI. XcmI-containing vector for direct cloning of PCR products. Biotechniques. 1997;22:812–4.
23. Xu X-M, Yoo M-H, Carlson BA, Gladyshev VN, Hatfield DL. Simultaneous knockdown of the expression of two genes using multiple shRNAs and subsequent knock-in of their expression. Nat Protoc. 2009;4:1338–48.
24. Weisheit G, Mertz D, Schilling K, Viebahn C. An efficient in situ hybridization protocol for multiple tissue sections and probes on miniaturized slides. Dev Genes Evol. 2002;212:403–6.
25. Glassmann A, Topka S, Wang-Eckardt L, Anders S, Weisheit G, Endl E, et al. Basic molecular fingerprinting of immature cerebellar cortical inhibitory interneurons and their precursors. Neuroscience. IBRO; 2009;159:69–82.
26. MTrackJ: A Java Program for Manual Object Tracking. Available from: http://www.imagescience.org/meijering/software/mtrackj/.
27. Kool M, Koster J, Bunt J, Hasselt NE, Lakeman A, Van Sluis P, et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. Array, editor. PLoS One. Public Library of Science; 2008;3:14.
28. Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M, et al. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol. 2011;29:3852–61.
29. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature. 2012;488:43–8.
30. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, McLaughlin ME, et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. Nature Publishing Group; 2002;415:436–42.
31. Székely GJ, Rizzo ML, Bakirov NK. Measuring and testing dependence by correlation of distances. Ann Stat. Institute of Mathematical Statistics; 2007;35:2769–94.
32. Kinney JB, Atwal GS, Jan QM. maximal information coefficient.:1–16.
33. Development Core Team, R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. 2005; Available from: http://www.citeulike.org/user/ftwaroch/article/2400517.
34. Sokal RR, Rohlf FJ. Biometry: the principles and practice of statistics in biological research. New York: Freeman; 1995.
35. Razick S, Magklaras G, Donaldson IM. iRefIndex: a consolidated protein interaction database with provenance. BMC Bioinforma. 2008;9:405.
36. Mora A, Donaldson IM. iRefR: an R package to manipulate the iRefIndex consolidated protein interaction database. BMC Bioinforma. 2011;12:455.
37. Csardi G, Nepusz T. The igraph software package for complex network research. Int J Complex Syst. 2006;1695:1695.
38. Schaller KL, Caldwell JH. Developmental and regional expression of sodium channel isoform NaCh6 in the rat central nervous system. J Comp Neurol. 2000;420:84–97.
39. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho Y-J, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2011;123:465–72.
40. Irizarry RA, Warren D, Spencer F, Kim IF, Biswal S, Frank BC, et al. Multiple-laboratory comparison of microarray platforms. Nat Methods. 2005;2:345–50.
41. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun X-W, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science. 2005;310:644–8.
42. Natarajan L, Pu M, Messer K. Exact statistical tests for the intersection of independent lists of genes. Ann Appl Stat. 2012;6:521–41.
43. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57.
44. Efron B. Microarrays, empirical Bayes and the two-groups model. Stat Sci. 2008;23:1–22.
45. Snuderl M, Batista A, Kirkpatrick ND, Ruiz de Almodovar C, Riedemann L, Walsh EC, et al. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell. 2013;152:1065–76.
46. Pambid MR, Berns R, Adomat HH, Hu K, Triscott J, Maurer N, et al. Overcoming resistance to Sonic Hedgehog inhibition by targeting p90 ribosomal S6 kinase in pediatric medulloblastoma. Pediatr Blood Cancer. 2014;61:107–15.
47. Cells T, Goulet B, Watson P, Poirier M, Leduy L, Be G, et al. Characterization of a tissue-specific CDP/Cux Isoform, p75, Activated in Breast. 2002;6625–33.
48. Goulet B, Truscott M, Nepveu A. A novel proteolytically processed CDP/Cux isoform of 90 kDa is generated by cathepsin L. Biol Chem. 2006;387:1285–93.
49. Moon NS, Premdas P, Truscott M, Leduy L, Bérubé G, Nepveu A. S phase-specific proteolytic cleavage is required to activate stable DNA binding by the CDP/Cut homeodomain protein. Mol Cell Biol. American Society for Microbiology; 2001;21:6332–45.
50. Maitra U, Seo J, Lozano MM, Dudley JP. Differentiation-induced cleavage of Cutl1/CDP generates a novel dominant-negative isoform that regulates mammary gene expression. Mol Cell Biol. American Society for Microbiology; 2006;26:7466–78.
51. Truscott M, Denault J-B, Goulet B, Leduy L, Salvesen GS, Nepveu A. Carboxyl-terminal proteolytic processing of CUX1 by a caspase enables transcriptional activation in proliferating cells. J Biol Chem. 2007;282:30216–26.
52. Lievens PM, Tufarelli C, Donady JJ, Stagg A, Neufeld EJ. CASP, a novel, highly conserved alternative-splicing product of the CDP/cut/cux gene, lacks cut-repeat and homeo DNA-binding domains, and interacts with full-length CDP in vitro. Gene. 1997;197:73–81.
53. Gillingham AK, Pfeifer AC, Munro S. CASP, the alternatively spliced product of the gene encoding the CCAAT-displacement protein transcription factor, is a Golgi membrane protein related to giantin. Mol Biol Cell. 2002;13:3761–74.
54. Limame R, Wouters A, Pauwels B, Fransen E, Peeters M, Lardon F, et al. Comparative analysis of dynamic cell viability, migration and invasion assessments by novel real-time technology and classic endpoint assays. PLoS One. 2012;7:e46536.
55. Lau K-M, Chan QKY, Pang JCS, Li KKW, Yeung WW, Chung NYF, et al. Minichromosome maintenance proteins 2, 3 and 7 in medulloblastoma: overexpression and involvement in regulation of cell migration and invasion. Oncogene. Nature Publishing Group; 2010;29:5475–89.
56. Studebaker AW, Kreofsky CR, Pierson CR, Russell SJ, Galanis E, Raffel C. Treatment of medulloblastoma with a modified measles virus. Neuro Oncol. 2010;12:1034–42.
57. Iii RLS, Sidransky D, Friedman HS, Bigner SH, Bigner DD, Vogelstein B, et al. Infrequent p53 gene mutations in medulloblastomas advances in brief infrequent p53 gene mutations in medulloblastomas1. 1991;4721–3.
58. Burov S, Jeon J-H, Metzler R, Barkai E. Single particle tracking in systems showing anomalous diffusion: the role of weak ergodicity breaking. Phys Chem Chem Phys. 2011;13:1800–12.
59. Thurner S, Wick N, Hanel R. Anomalous diffusion on dynamical networks: a model for interacting epithelial cell migration. 2003;320:475–84.
60. Epple LM, Griffiths SG, Dechkovskaia AM, Dusto NL, White J, Ouellette RJ, et al. Medulloblastoma exosome proteomics yield functional roles for extracellular vesicles. Castresana JS, editor. PLoS One. Public Library of Science; 2012;7:e42064.
61. Sansregret L, Goulet B, Harada R, Wilson B, Leduy L, Bertoglio J, et al. The p110 isoform of the CDP/Cux transcription factor accelerates entry into S phase. Mol Cell Biol. 2006;26:2441–55.
62. Truscott M, Harada R, Vadnais C, Robert F, Nepveu A. p110 CUX1 cooperates with E2F transcription factors in the transcriptional activation of cell cycle-regulated genes. Mol Cell Biol. 2008;28:3127–38.
63. Ripka S, König A, Buchholz M, Wagner M, Sipos B, Klöppel G, et al. WNT5A—target of CUTL1 and potent modulator of tumor cell migration and invasion in pancreatic cancer. Carcinogenesis. 2007;28:1178–87.
64. Ard PG, Chatterjee C, Kunjibettu S, Adside LR, Gralinski LE, McMahon SB. Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes. Mol Cell Biol. 2002;22:5650–61.
65. Lee J, Beliakoff J, Sun Z. The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor. Nucleic Acids Res. 2007;35:4523–34.
66. Hock AK, Vigneron AM, Carter S, Ludwig RL, Vousden KH. Regulation of p53 stability and function by the deubiquitinating enzyme USP42. EMBO J. 2011;30:4921–30.
67. Puca R, Nardinocchi L, Givol D, D’Orazi G. Regulation of p53 activity by HIPK2: molecular mechanisms and therapeutical implications in human cancer cells. Oncogene. 2010;29:4378–87.
68. Zhang X-C, Chen J, Su C-H, Yang H-Y, Lee M-H. Roles for CSN5 in control of p53/MDM2 activities. J Cell Biochem. 2008;103:1219–30.
69. Amson R, Pece S, Lespagnol A, Vyas R, Mazzarol G, Tosoni D, et al. Reciprocal repression between P53 and TCTP. Nat Med. 2012;18:91–9.
70. Woods NT, Mesquita RD, Sweet M, Carvalho MA, Li X, Liu Y, et al. Charting the landscape of tandem BRCT domain-mediated protein interactions. Sci Signal. 2012;5:rs6.
71. Vadnais C, Davoudi S, Afshin M, Harada R, Dudley R, Clermont P-L, et al. CUX1 transcription factor is required for optimal ATM/ATR-mediated responses to DNA damage. Nucleic Acids Res. 2012;40:4483–95.
72. Baxter EW, Milner J. p53 Regulates LIF expression in human medulloblastoma cells. J Neurooncol. 2010;97:373–82.
73. Frappart P-O, Lee Y, Russell HR, Chalhoub N, Wang Y-D, Orii KE, et al. Recurrent genomic alterations characterize medulloblastoma arising from DNA double-strand break repair deficiency. Proc Natl Acad Sci U S A. 2009;106:1880–5.
74. Wang Y-C, Peterson SE, Loring JF. Protein post-translational modifications and regulation of pluripotency in human stem cells. Cell Res. Nature Publishing Group; 2013;1–18.
75. Panier S, Durocher D. Push back to respond better: regulatory inhibition of the DNA double-strand break response. Nat Rev Mol Cell Biol. Nature Publishing Group; 2013;14:661–72.
76. Xu J, Zhu W, Xu W, Cui X, Chen L, Ji S, et al. Silencing of MBD1 reverses pancreatic cancer therapy resistance through inhibition of DNA damage repair. Int J Oncol. 2013;42:2046–52.
77. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39:162–4.
78. Alter BP, Rosenberg PS, Brody LC. Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. J Med Genet. 2007;44:1–9.
79. Li P, Du F, Yuelling LW, Lin T, Muradimova RE, Tricarico R, et al. A population of Nestin-expressing progenitors in the cerebellum exhibits increased tumorigenicity. Nat Neurosci. Nature Publishing Group; 2013;16:1737–44.
80. Li J, Han YR, Plummer MR, Herrup K. Cytoplasmic ATM in neurons modulates synaptic function. Curr Biol. Elsevier Ltd; 2009;19:2091–6.
81. Ramdzan ZM, Vadnais C, Pal R, Vandal G, Cadieux C, Leduy L, et al. RAS transformation requires CUX1-dependent repair of oxidative DNA damage. PLoS Biol. 2014;12:e1001807.
82. Genovesi LA, Ng CG, Davis MJ, Remke M, Taylor MD, Adams DJ, et al. Sleeping Beauty mutagenesis in a mouse medulloblastoma model defines networks that discriminate between human molecular subgroups. Proc Natl Acad Sci U S A. 2013;110:E4325–34.
83. Weinberg RA. The cat and mouse games that genes, viruses, and cells play. Cell. 1997;88:573–5.
84. Leonard JM, Ye H, Wetmore C, Karnitz LM. Sonic Hedgehog signaling impairs ionizing radiation-induced checkpoint activation and induces genomic instability. J Cell Biol. 2008;183:385–91.
85. Diede SJ, Yao Z, Keyes CC, Tyler AE, Dey J, Hackett CS, et al. Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. Epigenetics. 2013;8.
86. Biss M, Xiao W. Selective tumor killing based on specific DNA-damage response deficiencies. Cancer Biol Ther. 2012;13:239–46.
87. Ljungman M. Targeting the DNA damage response in cancer. Chem Rev. 2009;109:2929–50.
88. Fernandez-L A, Squatrito M, Northcott P, Awan A, Holland EC, Taylor MD, et al. Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene. 2012;31:1923–37.
89. Künkele A, De Preter K, Heukamp L, Thor T, Pajtler KW, Hartmann W, et al. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas. Neuro Oncol. 2012;14:859–69.